dermatology

A respected RNAi therapeutics company.

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today positive top-line outcomes from its ongoing Stage I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treating TTR-mediated amyloidosis online pharmacy Norway . The business is normally reporting that ALN-TTRsc accomplished robust and statistically significant knockdown of serum TTR protein levels of higher than 80 percent in healthy volunteer subjects, in line with results for ALN-TTRsc previously reported in non-human primates. In addition, to day ALN-TTRsc was found to be generally secure and well tolerated. Continue reading